This month, Abbott announced a string of partnerships, with Tandem Diabetes Care being the latest, to combine its future dual glucose-ketone monitoring sensor with automated insulin delivery (AID) systems. The collaboration adds to Abbott’s growing CGM ecosystem, following earlier integrations with Beta Bionics, Sequel Med Tech, and European partner Ypsomed. The dual analyte sensor is expected to launch in the first half of 2026, and analysts at Height Capital Markets and Leerink Partners say it could help drive adaption of Abbott’s continuous glucose monitoring portfolio.
Medtech Insight spoke with Chris Scoggins, executive vice president of diabetes care at Abbott, ahead of the 85th annual scientific...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?